Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of JPY 2.69 trillion. The enterprise value is 3.43 trillion.

Market Cap	2.69T
Enterprise Value	3.43T

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.88% in one year.

Current Share Class	n/a
Shares Outstanding	1.79B
Shares Change (YoY)	-0.88%
Shares Change (QoQ)	-0.44%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	58.47%
Float	1.79B

Valuation Ratios

PE Ratio	n/a
Forward PE	21.00
PS Ratio	1.44
PB Ratio	1.80
P/TBV Ratio	n/a
P/FCF Ratio	21.08
P/OCF Ratio	n/a
PEG Ratio	0.19

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.62, with an EV/FCF ratio of 26.85.

EV / Earnings	-59.64
EV / Sales	1.83
EV / EBITDA	8.62
EV / EBIT	17.37
EV / FCF	26.85

Financial Position

The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.61.

Current Ratio	1.04
Quick Ratio	0.73
Debt / Equity	0.61
Debt / EBITDA	2.29
Debt / FCF	7.17
Interest Coverage	11.16

Financial Efficiency

Return on equity (ROE) is -3.83% and return on invested capital (ROIC) is 5.24%.

Return on Equity (ROE)	-3.83%
Return on Assets (ROA)	3.67%
Return on Invested Capital (ROIC)	5.24%
Return on Capital Employed (ROCE)	8.72%
Revenue Per Employee	126.58M
Profits Per Employee	-3.89M
Employee Count	14,754
Asset Turnover	0.55
Inventory Turnover	1.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.66% in the last 52 weeks. The beta is 0.16, so Astellas Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	-10.66%
50-Day Moving Average	1,481.21
200-Day Moving Average	1,614.06
Relative Strength Index (RSI)	58.93
Average Volume (20 Days)	6,614,750

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of JPY 1.87 trillion and -57.43 billion in losses. Loss per share was -32.07.

Revenue	1.87T
Gross Profit	1.52T
Operating Income	200.46B
Pretax Income	-77.98B
Net Income	-57.43B
EBITDA	400.55B
EBIT	200.46B
Loss Per Share	-32.07

Full Income Statement

Balance Sheet

The company has 179.87 billion in cash and 915.36 billion in debt, giving a net cash position of -735.50 billion or -410.87 per share.

Cash & Cash Equivalents	179.87B
Total Debt	915.36B
Net Cash	-735.50B
Net Cash Per Share	-410.87
Equity (Book Value)	1.49T
Book Value Per Share	834.64
Working Capital	51.36B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 165.42 billion and capital expenditures -37.83 billion, giving a free cash flow of 127.58 billion.

Operating Cash Flow	165.42B
Capital Expenditures	-37.83B
Free Cash Flow	127.58B
FCF Per Share	71.27

Full Cash Flow Statement

Margins

Gross margin is 81.50%, with operating and profit margins of 10.73% and -3.07%.

Gross Margin	81.50%
Operating Margin	10.73%
Pretax Margin	-4.18%
Profit Margin	-3.07%
EBITDA Margin	21.45%
EBIT Margin	10.73%
FCF Margin	6.83%

Dividends & Yields

This stock pays an annual dividend of 74.00, which amounts to a dividend yield of 4.95%.

Dividend Per Share	74.00
Dividend Yield	4.95%
Dividend Growth (YoY)	5.71%
Years of Dividend Growth	9
Payout Ratio	n/a
Buyback Yield	0.88%
Shareholder Yield	5.82%
Earnings Yield	-2.14%
FCF Yield	4.74%

Dividend Details

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 1.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.92
Piotroski F-Score	n/a